{{cart_num}}
My Cart> Small Molecule Compounds > Inhibitors & Antagonists & Agonists > Angiogenesis > ErlotinibCAS：183321-74-6
Molecular Formula：C22H23N3O4
Molecular Weight：393.44
Storage：Powder:-20℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year
Purity：≥98%
Appearance：White to yellow Solid
Qty：
Size：
| CAS | 183321-74-6 |
| Name | Erlotinib |
| Molecular Formula | C22H23N3O4 |
| Molecular Weight | 393.44 |
| Solubility | Soluble in DMSO(Need ultrasonic) |
| Purity | ≥98% |
| Appearance | White to yellow Solid |
| Storage | Powder:-20℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| EC | EINECS 689-196-2 |
| MDL | MFCD08063588 |
| SMILES | C#CC1=CC=CC(NC2=NC=NC3=C2C=C(C(OCCOC)=C3)OCCOC)=C1 |
| InChIKey | AAKJLRGGTJKAMG-UHFFFAOYSA-N |
| InChI | InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25) |
| PubChem CID | 176870 |
| Target Point | EGFR |
| Passage | Angiogenesis;Protein Tyrosine Kinase/RTK; JAK/STAT Signaling |
| Background | Erlotinib is an EGFR inhibitor. |
| Biological Activity | Erlotinib (CP-358774) is a directly acting EGFR tyrosine kinase inhibitor， with an IC50 of 2 nM for human EGFR. Erlotinib reduces EGFR autophosphorylation in intact tumor cells with an IC50 of 20 nM. Erlotinib is used for the treatment of non-small cell lung cancer. Erlotinib is a click chemistry reagent， itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.[1-3] |
| Data Literature Source | [1]. Moyer JD， et al. Induction of apoptosis and cell cycle arrest by CP-358，774， an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 1997， 57(21)， 4838-4848. [2]. Ali S， et al. Apoptosis-inducing effect of erlotinib is potentiated by 3，3-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer. Mol Cancer Ther， 2008， 7(6)， 1708-1719. [3]. Wada Y， et al. Epidermal growth factor receptor inhibition with erlotinib partially prevents cisplatin-induced nephrotoxicity in rats. PLoS One. 2014 Nov 12;9(11):e111728. |
| Unit | Bottle |
| Specification | 50mg |
Remark：These protocols are for reference only. Solarbio does not independently validate these methods.
Note：
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.
Manual Download
